Biocon Capital Structure Change
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale on July 14, 2026.
Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale.
Biocon allotted 8.78 million equity shares via preferential issue at Rs. 376.41 per share. The Rs. 330.73 Crore fund-raise increased paid-up capital.